• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Toward Personalized Sexual Medicine (Part 2): Testosterone Combined with a PDE5 Inhibitor Increases Sexual Satisfaction in Women with HSDD and FSAD, and a Low Sensitive System for Sexual Cues
【24h】

Toward Personalized Sexual Medicine (Part 2): Testosterone Combined with a PDE5 Inhibitor Increases Sexual Satisfaction in Women with HSDD and FSAD, and a Low Sensitive System for Sexual Cues

机译：走向个性化性医学（第2部分）：睾丸激素与PDE5抑制剂相结合可提高HSDD和FSAD妇女的性满意度，并降低对性暗示的敏感性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction. Low sexual desire in women may result from a relative insensitivity of the brain for sexual cues. Administration of sublingual 0.5mg testosterone (T) increases the sensitivity of the brain to sexual cues. Sexual stimulation in the brain is necessary for phosphodiesterase type 5 inhibitor (PDE5i)-mediated increase in genital sexual response. Accordingly, a single dose of T+PDE5i might enhance sexual responsiveness, especially in women with low sensitivity for sexual cues. Aim. To assess the hypothesis that treatment with on-demand use of T+PDE5i improves sexual functioning, particularly in women who suffer from Hypoactive Sexual Desire Disorder (HSDD) as the result of a relative insensitivity for sexual cues. Methods. In a randomized, double-blind, placebo-controlled, crossover design, 56 women with HSDD underwent three medication treatment regimes (placebo, T+PDE5i, and T with a serotonin 1A receptor agonist; see also parts 1 and 3), which lasted 4 weeks each. In a participant-controlled ambulatory psychophysiological experiment at home (the first week of each drug treatment), physiological and subjective indices of sexual functioning were measured. In a bedroom experiment (the subsequent 3 weeks), sexual functioning was evaluated following each sexual event after the self-administration of study medication. Subjective evaluation of sexual functioning was also measured by weekly and monthly reports. Main Outcome Measures. Subjective: sexual satisfaction, experienced genital arousal, sexual desire. Physiological: vaginal pulse amplitude. Cognitive: preconscious attentional bias. Results. T+PDE5i, as compared with placebo, significantly improved physiological and subjective measures of sexual functioning during ambulatory psychophysiological lab conditions at home and during the sexual events, in women with low sensitivity for sexual cues. Conclusions. The present study demonstrated that on-demand T+PDE5i is a potentially promising treatment for women with HSDD, particularly in women with low sensitivity for sexual cues. ? 2012 International Society for Sexual Medicine.
机译：介绍。女性性欲低下可能是由于大脑对性暗示相对不敏感所致。舌下0.5mg睾丸激素（T）的使用会增加大脑对性暗示的敏感性。大脑中的性刺激对于5型磷酸二酯酶（PDE5i）介导的生殖器性反应的增加是必需的。因此，单剂量的T + PDE5i可能会增强性反应能力，尤其是对性暗示敏感性较低的女性。目标。评估以下假设，即按需使用T + PDE5i可以改善性功能，尤其是对性暗示相对不敏感而导致性欲减退（HSDD）不足的女性。方法。在一项随机，双盲，安慰剂对照的交叉设计中，对56名HSDD的妇女进行了三种药物治疗方案（安慰剂，T + PDE5i和T与血清素1A受体激动剂;另请参阅第1部分和第3部分），历时持续每个4周。在家里由参与者控制的门诊心理生理实验中（每次药物治疗的第一周），对性功能的生理和主观指标进行了测量。在一个卧室实验中（随后的3周），在自我服用研究药物后，每次性行为后都要评估其性功能。还通过每周和每月的报告对性功能进行主观评估。主要观察指标。主观：性满足，经历过生殖器唤醒，性欲。生理：阴道脉搏振幅。认知：前瞻性注意偏见。结果。与安慰剂相比，T + PDE5i在对性暗示敏感度较低的女性中，在家中及非性行为发生时在非卧床心理生理实验室条件下和性行为期间，显着改善了性功能的生理和主观测量。结论。本研究表明，按需使用T + PDE5i是治疗HSDD的妇女的一种有前途的治疗方法，尤其是对性暗示敏感性较低的妇女。 ？ 2012年国际性医学学会。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号